摘要
目的探讨长春瑞滨联合顺铂(NP方案)治疗蒽环类和(或)紫杉类耐药转移性三阴性乳腺癌的近期疗效与安全性。方法 30例蒽环类和(或)紫杉类耐药的转移性三阴性乳腺癌患者接受长春瑞滨联合顺铂方案化疗:长春瑞滨25 mg/m2,d1、d8,静脉滴注;顺铂25 mg/m2,静脉滴注,d2～d4。21天为一周期,2周期治疗结束后评价疗效。结果 30例患者中,完全缓解(CR)1例(3.3%),部分缓解(PR)16例(53.3%),稳定(SD)10例(33.3%),进展(PD)3例(10.0%),客观有效率(CR+PR)为56.7%。主要不良反应是Ⅰ～Ⅱ级骨髓抑制和胃肠道反应。结论长春瑞滨联合顺铂方案是治疗蒽环类和(或)紫杉类耐药转移性三阴性乳腺癌安全有效的解救方案。
Objective To investigate the short-term efficacy and safety of vinorelbine plus cisplatin for anthracycline and（or） taxane-resistant metastatic triple-negative breast cancer.Methods Thirty patients with anthracycline and（or） taxane-resistant metastatic triple-negative breast cancer patients received vinorelbine and cisplatin regimen：vinorelbine 25 mg/m2,d1,d8;cisplatin 25 mg/m2,d2~d4.Treatments were repeated every 21 days and response rate was evaluated every two cycles.Results Complete remission（CR）,partial remission（PR）,stable disease（SD） and progressive disease（PD） were 1 case（3.3%）,16 cases（53.3%）,10 cases（33.3%） and 3 cases（10.0%）,respectively.Objective response rate was 56.7%.The main adverse reactions were bone marrow suppression and gastrointestinal reactions.Conclusion Combination of vinorelbine and cisplatin was an effective and well-tolerated rescue regimen in anthracycline and（or） taxane-resistant metastatic TNBC patients.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2012年第6期725-727,共3页
Cancer Research on Prevention and Treatment
关键词
三阴性乳腺癌
长春瑞滨
顺铂
蒽环类和(或)紫杉类耐药
Triple-negative breast cancer
Vinorelbine
Cisplatin
Anthracycline and（or） taxane-resistant
